Indian pharmas seek to protect their edge

Arguing that India will become a "contract manufacturing center" and "lose its edge," industry groups are seeking restrictions on foreign mergers and acquisitions. A panel of government officials recommended a foreign direct investment cap of 49% for brownfield projects while providing no cap for greenfield investments. But planning commission deputy chairman Montek Singh Ahluwalia said on Monday that he sees "no case for rollback" of FDI in the pharma sector. Story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.